Hansa Biopharma Ab Stock Current Valuation
| HNSBF Stock | USD 2.93 0.00 0.00% |
Valuation analysis of Hansa Biopharma AB helps investors to measure Hansa Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Hansa Biopharma's price fluctuation is unstable at this time. Calculation of the real value of Hansa Biopharma AB is based on 3 months time horizon. Increasing Hansa Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Hansa Biopharma AB is useful when determining the fair value of the Hansa pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Hansa Biopharma. Since Hansa Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hansa Pink Sheet. However, Hansa Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.93 | Real 2.95 | Hype 2.93 |
The real value of Hansa Pink Sheet, also known as its intrinsic value, is the underlying worth of Hansa Biopharma AB Company, which is reflected in its stock price. It is based on Hansa Biopharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Hansa Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hansa Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hansa Biopharma AB helps investors to forecast how Hansa pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hansa Biopharma more accurately as focusing exclusively on Hansa Biopharma's fundamentals will not take into account other important factors: Hansa Biopharma AB Company Current Valuation Analysis
Hansa Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hansa Biopharma Current Valuation | 189.89 M |
Most of Hansa Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Hansa Biopharma AB has a Current Valuation of 189.89 M. This is 98.68% lower than that of the Healthcare sector and 95.91% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.86% higher than that of the company.
Hansa Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in current valuation category among related companies.
Hansa Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 189.89 M | |||
| Shares Outstanding | 52.44 M | |||
| Shares Owned By Insiders | 7.37 % | |||
| Shares Owned By Institutions | 41.33 % | |||
| Price To Earning | (46.57) X | |||
| Price To Book | 6.59 X | |||
| Price To Sales | 16.29 X | |||
| Revenue | 33.88 M | |||
| Gross Profit | 116.05 M | |||
| EBITDA | (538.83 M) | |||
| Net Income | (548.28 M) | |||
| Cash And Equivalents | 60.15 M | |||
| Cash Per Share | 1.58 X | |||
| Debt To Equity | 2.29 % | |||
| Current Ratio | 6.42 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (481.17 M) | |||
| Earnings Per Share | (0.65) X | |||
| Number Of Employees | 150 | |||
| Beta | 0.88 | |||
| Market Capitalization | 274.8 M | |||
| Total Asset | 1.01 B | |||
| Working Capital | 86 M | |||
| Current Asset | 105 M | |||
| Current Liabilities | 19 M | |||
| Net Asset | 1.01 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |